期刊文献+

盐酸替罗非班在冠心病治疗中的进展 被引量:11

Coronary Heart Disease Treated with Tirofiban Hydrochloride
下载PDF
导出
摘要 抗血小板治疗在冠状动脉粥样硬化性心脏病治疗中占有重要地位。盐酸替罗非班是一种新型可逆性非肽类血小板表面糖蛋白Ⅱb/Ⅲa受体拮抗剂,可竞争性抑制纤维蛋白原与血小板糖蛋白ⅡbⅢ/a受体的结合,抑制血小板聚集,延长出血时间,抑制血栓形成。近年来该药广泛应用于冠心病治疗,特别是在急性冠脉综合征以及经皮冠状动脉介入治疗中发挥重要作用,是极具前途的抗血小板药物。 Antiplatelet therapy plays an important role in the treatment of coronary atherosclerotic heart disease. As a kind of patelet glycoprotein Ⅱb/Ⅲa a receptor antagonists, tirofiban hydrochloride can competitive inhibit the combination of fibrinogen and platelet glycoprotein Ⅱb/Ⅲa a receptor,and prolong bleeding time,reduce thrombosis. It Is a very promising anti-platelet drug widely used in the treatment of coronary heart disease, especially in acute coronary syndromes and percutaneous coronary intervention in recent years.
作者 王雪梅 李鹏
出处 《医学综述》 2009年第18期2791-2793,共3页 Medical Recapitulate
关键词 血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂 盐酸替罗非班 冠状动脉粥样硬化性心脏病 Patelet glycoprotein Ⅱb/Ⅲa a receptor Tirofiban hydrochloride Coronary atheroselerotic heart disease
  • 相关文献

参考文献16

  • 1Elmouchi DA,Bates ER.Platelet glycoprotein Ⅱb/Ⅲa inhibitou therapy in non-ST segment elevation acute coronary syndromes[J].Minerva Cardioangiol,2003,51(5):547-560.
  • 2The EPIC investigators.Use of a monoclonal antibody directed against the glycoprotein Ⅱb/Ⅲa receptor in high-risk coronary angioplasty[J].N Engl J Med,1994,330(14):956-961.
  • 3The EPLOG investigators.Platelet glycoprotein Ⅱb/Ⅲa receptor blockade and low-dose heparin during percutaneous coronary revascularization[J].N Engl J Med,1997,336(24):1689-1696.
  • 4The CAPTURE investigators.Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina:The CAPTURE study[J].Lancert,1997,349(9063):1429-1435.
  • 5The IMPACT-II investigators.Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention:IMPACT-II[J].Lancet,1997,349(9063):1422-1428.
  • 6The RESTORE investigators.Effects of platelet glycoprotein Ⅱb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty[J].Circulation,1997,96(5):1445-1453.
  • 7Montalescot G,Barragan P,W ittenberg O.Abciximab associated with primary angioplasty and stenting in acute myocardial infarction:The ADM IRAL study,30-day final results[J].Circulation,1999,100(Supp 1):187.
  • 8Karvouni I,Katritsis DG,bannidis JP.Intravenous glycoprotein Ⅱb/Ⅲa receptor antagonists reduce mortality after percutaneous coronary interventions[J].J Am Coll Cardiol,2003,41(1):26-32.
  • 9Valgimgli M,Percoco C,Malagutti P,et al.Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction:a randomized troal[J].JAMA,2005,293(17):2109-2117.
  • 10Warnholtz A,Ostad MA,Heitzer T,et al.Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease[J].Am J Cardiol,2005,95(1):20-23.

同被引文献94

引证文献11

二级引证文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部